In addition, some tumours can evade immune elimination, because of overexpression of PD‐L1/PD‐1.8, 9 Inhibitors of PD‐L1/PD‐1 have been approved by Food and Drug Administration (FDA) as second‐line treatments for lung cancer, because of their therapeutic benefit in clinical trials. Here, PDCD1 is linked to lung cancer.